Literature DB >> 19060266

Regulatory function of CpG-activated B cells in late-phase experimental allergic conjunctivitis.

Dai Miyazaki1, Chuan Hui Kuo, Takeshi Tominaga, Yoshitsugu Inoue, Santa Jeremy Ono.   

Abstract

PURPOSE: To determine how CpG, an immunostimulatory sequence, affects experimental allergic conjunctivitis and to determine the mechanisms of its action.
METHODS: Experimental allergic conjunctivitis was induced in mice to investigate the suppressive mechanism of CpG treatment. Cytokine profiling, fluorescence-activated cell sorting analyses, and adoptive transfer were used to analyze suppressive mechanisms after CpG treatment.
RESULTS: Administration of the CpG oligonucleotide induced significant splenomegaly. Adoptive transfer of the splenocytes isolated from CpG-treated mice was able to confer resistance to allergen-induced inflammatory responses in recipient mice. CpG treatment led to a transient upregulation of IL-1ra, IL-18, IL-1alpha, and IL-12 in the spleen, draining lymph nodes, and conjunctiva. In contrast, IL-10 showed a marked and sustained induction in the inductive and effector tissues. Splenomegaly after CpG exposure was reduced in IL-10-deficient mice, indicating that IL-10 is required for immune remodeling of the spleen. Analyses of allergen-sensitized mice deficient in IL-10 exacerbated the late-phase inflammatory responses. Fluorescence-activated cell sorting analysis of the CpG-induced splenocyte subsets showed that the predominant source of IL-10 was B220(+) CD19(+) CD23(+)IgM(+)CD40(+)class II(high) follicular B cells. Adoptive transfer of IL-10-deficient B cells exacerbated eosinophilia. Transfer of an expanded population of cells after CpG treatment, including IL-10-secreting follicular B cells, protected against eosinophilia.
CONCLUSIONS: CpG treatment provided B cell-mediated regulation of immune responses and B cell differentiation in CpG-induced immune remodeling with the use of IL-10.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060266     DOI: 10.1167/iovs.08-2701

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.

Authors:  Qing Ding; Melissa Yeung; Geoffrey Camirand; Qiang Zeng; Hisaya Akiba; Hideo Yagita; Geetha Chalasani; Mohamed H Sayegh; Nader Najafian; David M Rothstein
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

Review 2.  Role of Circulating Immune Cells in Stroke and Preconditioning-Induced Protection.

Authors:  Raffaella Gesuete; Susan L Stevens; Mary P Stenzel-Poore
Journal:  Acta Neurochir Suppl       Date:  2016

Review 3.  Role of B cells in tolerance induction.

Authors:  James I Kim; David M Rothstein; James F Markmann
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

4.  Interleukin-10 production and T cell-suppressive capacity in B cell subsets from atherosclerotic apoE -/- mice.

Authors:  Héctor Rincón-Arévalo; Janny Villa-Pulgarín; Jorge Tabares; Mauricio Rojas; Gloria Vásquez; José R Ramírez-Pineda; Diana Castaño; Lina M Yassin
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

Review 5.  CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance.

Authors:  Guillem Montamat; Cathy Leonard; Aurélie Poli; Ludger Klimek; Markus Ollert
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells.

Authors:  Hamid Hosseini; Li Yi; Peter Kanellakis; Anh Cao; Christopher Tay; Karlheinz Peter; Alex Bobik; Ban-Hock Toh; Tin Kyaw
Journal:  J Am Heart Assoc       Date:  2018-06-23       Impact factor: 5.501

Review 7.  Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Kongyang Ma; Wenhan Du; Xiaohui Wang; Shiwen Yuan; Xiaoyan Cai; Dongzhou Liu; Jingyi Li; Liwei Lu
Journal:  Int J Mol Sci       Date:  2019-11-29       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.